Group 1 - The article introduces Professor Song Zhenju, who holds multiple prestigious positions in emergency medicine and clinical research, including Director of the Emergency Department at Fudan University Zhongshan Hospital and Vice President of the same hospital [1] - Professor Song has led numerous national and provincial research projects, published extensively in high-impact journals, and holds multiple patents, indicating a strong research background and contributions to the field [1] Group 2 - The research directions focus on Acute Respiratory Distress Syndrome (ARDS) mechanisms and interventions, organ damage from sepsis, and mechanisms and interventions for acute poisoning [6] Group 3 - Recruitment is open for postdoctoral positions in fields such as Clinical Medicine, Life Sciences, Biology, Biomedical Engineering, and Pharmacy [3] - Candidates must be under 35 years old, have a strong academic background, and have published at least one SCI paper [5] Group 4 - Compensation will follow national and Fudan University standards, with additional rewards for outstanding performance during the contract period [7] Group 5 - Applicants are required to submit a detailed CV, proof of doctoral degree, and 1-3 representative papers [8] - Contact information for applications is provided, with specific instructions for email subject lines [9][10]

Group 1 - Sanofi is acquiring Blueprint Medicines Corp for $9.1 billion in equity value, enhancing its pipeline in rare immune diseases [1][2] - The acquisition price is set at $129 per share, representing a 27% premium over Blueprint's closing price last Friday [1] - Blueprint shareholders will receive a contingent value right (CVR) worth an additional $2 to $4 per share if the BLU-808 drug meets certain development and regulatory milestones [1] Group 2 - This acquisition reflects Sanofi's ambition to establish a leadership position in immunology, following a previous announcement to acquire Dren Bio, Inc. for up to $1.9 billion [1] - Blueprint Medicines has a strong clinical network among specialists and a pipeline that includes several immunotherapy candidates [2] - The total value of the transaction, including potential CVR payments, is approximately $9.5 billion, with Sanofi expecting the deal to close in the third quarter without significant impact on its 2025 financial guidance [2]